Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026)
Recursion Pharmaceuticals (RXRX) reported Return on Capital Employed of 45.83% for Q1 2026, up 66.0% on a YoY basis from 27.61% in Q1 2025, and up 8.85% quarter-over-quarter from 50.28% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported Return on Capital Employed for 6 years, with the latest figure at 45.83% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 66.0% year-over-year to 45.83%; the trailing twelve-month figure through Mar 2026 stood at 45.83% (up 66.0% YoY), and the FY2025 full-year result was 49.34%, up 612.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 45.83%, up from 50.28% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.5% in Q1 2022, with the low at 70.8% in Q1 2024.
- Historically, Return on Capital Employed has averaged 52.55% across 5 years, with a median of 51.61% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 2542 bps — and 2025, when it surged 2431 bps.
- Recursion Pharmaceuticals' Return on Capital Employed stood at 44.18% in 2022, then slumped by 44 bps to 63.75% in 2023, then climbed by 17 bps to 53.22% in 2024, then gained by 6 bps to 50.28% in 2025, then advanced by 9 bps to 45.83% in 2026.
- The last three Return on Capital Employed figures came in at 45.83% (Q1 2026), 50.28% (Q4 2025), and 60.51% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -45.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.83% |
| Dec 31, 2025 | -50.28% |
| Sep 30, 2025 | -60.51% |
| Jun 30, 2025 | -57.00% |
| Mar 31, 2025 | -46.48% |
| Dec 31, 2024 | -53.22% |
| Sep 30, 2024 | -61.37% |
| Jun 30, 2024 | -68.08% |
| Mar 31, 2024 | -70.80% |
| Dec 31, 2023 | -63.75% |
| Sep 30, 2023 | -56.27% |
| Jun 30, 2023 | -51.61% |
| Mar 31, 2023 | -45.37% |
| Dec 31, 2022 | -44.18% |
| Sep 30, 2022 | -44.67% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.50% |
| Dec 31, 2021 | -31.09% |
| Sep 30, 2021 | -22.56% |
| Jun 30, 2021 | -26.21% |